PHASE 3 TRIAL OF TUMOR TREATING FIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: ENGOT-OV50/GOG-329/INNOVATE-3

被引：0
|
作者：
Vergote, I. [1 ]
Salutari, V. [2 ]
Cibula, D. [3 ]
Korach, J. [4 ]
Samartzis, E. P. [5 ]
Sehouli, J. [6 ]
Fossati, R. [7 ]
Martin, A. G. [8 ]
Tsibulak, I. [9 ]
Slomovitz, B. [10 ]
Coleman, R. [11 ]
Monk, B. [12 ]
Thaker, P. [13 ]
O'Malley, D. [14 ]
机构：
[1] Leuven Canc Inst, Leuven, Belgium
[2] Fdn Policl Univ Agostino Gemelli, Rome, Italy
[3] Charles Univ Hosp, Prague, Czech Republic
[4] Chaim Sheba Med Ctr, Ramat Gan, Israel
[5] Univ Spital Zurich, Zurich, Switzerland
[6] Charite Frauenklinik, Berlin, Germany
[7] IRCCS Ist Ric Farmacol, Milan, Italy
[8] Clin Univ Navarra, Navarra, Spain
[9] Med Univ Innsbruck, Innsbruck, Austria
[10] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[11] MD Anderson Canc Ctr, Houston, TX USA
[12] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[13] Washington Univ Gynecol Oncol, Washington, DC USA
[14] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-IGCS.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS20_138
引用
收藏
页码：A147 / A148
页数：2
相关论文
共 50 条
  • [31] OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel plus /- novel agents in platinum-resistant ovarian cancer: Vistusertib
    Banerjee, S.
    Lewsley, L-A.
    Clamp, A. R.
    Krell, J.
    Herbertson, R.
    Glasspool, R. M.
    Orbegoso, C.
    Green, C.
    Kristeleit, R. S.
    Gourley, C.
    Cambell, C.
    Banerji, U.
    Shepherd, C.
    Brugger, W.
    Chudleigh, L.
    Hanif, A.
    McNeish, I. A.
    Paul, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 403 - +
  • [32] Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, Ron E.
    Goff, Barbara Ann
    Childs, Jennifer
    Higgins, Doreen
    Gooley, Theodore
    Fintak, Patricia A.
    Buening, Barbara
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial: Mirvetuximab Soravtansine (MIRV) Prolongs Overall Survival vs Investigator's Choice Chemotherapy (IC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha (FRa) Expression
    Hilpert, Felix
    Harter, Philipp
    Lorusso, Domenica
    Konecny, Gottfried. E.
    Banerjee, Susana
    Colombo, Nicoletta
    Wang, Yuemei
    Stec, James
    Method, Michael
    Van Gorp, Toon
    Moore, Kathleen
    de Gregorio, Nikolaus
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 91 - 91
  • [34] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
    Bello, Diana
    Van Gorp, Toon
    Konecny, Gottfried E.
    Estevez-Garcia, Purificacion
    Moroney, John William
    Banerjee, Susana N.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Parma, Gabriella
    Sonnenburg, DanielW
    Roszak, Andrzej
    Lalisang, Roy Iqbal
    Shapira-Frommer, Ronnie
    Klat, Jaroslav
    Wang, Yuemei
    Method, Michael W.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).
    Pignata, Sandro
    Lorusso, Domenica
    Scambia, Giovanni
    Sambataro, Daniela
    Tamberi, Stefano
    Cinieri, Saverio
    Mosconi, Anna Maria
    Orditura, Michele
    Bartolini, Stefania
    Arcangeli, Valentina
    Panici, Pierluigi Benedetti
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Raspagliesi, Francesco
    Salutari, Vanda
    Daniele, Gennaro
    Piccirillo, Maria Carmela
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
    Olawaiye, Alexander B.
    Kim, Jae-Weon
    Bagameri, Andrea
    Bishop, Erin
    Chudecka-Glaz, Anita
    Devaux, Alix
    Gladieff, Laurence
    Gordinier, Mary E.
    Korach, Jacob
    McCollum, Michael E.
    Mileshkin, Linda
    Monk, Bradley J.
    Nicum, Shibani
    Nogueira-Rodrigues, Angelica
    Oaknin, Ana
    O'Malley, David M.
    Orlando, Mauro
    Dreiling, Lyndah
    Tudor, Julia C.
    Lorusso, Domenica
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (04)
  • [37] Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
    Vergote, Ignace
    Scambia, Giovanni
    O'Malley, David M.
    Van Calster, Ben
    Park, Sang-Yoon
    del Campo, Josep M.
    Meier, Werner
    Bamias, Aristotelis
    Colombo, Nicofetta
    Wenham, Robert M.
    Covens, Al
    Marth, Christian
    Mirza, Mansoor Raza
    Kroep, Judith R.
    Ma, Haijun
    Pickett, Cheryl A.
    Monk, Bradley J.
    LANCET ONCOLOGY, 2019, 20 (06): : 862 - 876
  • [38] Chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial
    Mahner, S.
    Lueck, H. -J.
    Grischke, E. -M.
    Rau, J.
    Gropp-Meier, M.
    Schmalfeldt, B.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Huels, R.
    Gerber, B.
    du Bois, A.
    Marme, F.
    Hilpert, F.
    Canzler, U.
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 97 - 97
  • [39] Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer
    Husain, Amreen
    Wang, Yan
    Hanker, Lars C.
    Ojeda, Belen
    Anttila, Maarit
    Breda, Enrico
    Vuylsteke, Peter
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2016, 142 (03) : 465 - 470
  • [40] Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
    Poveda, Andres M.
    Selle, Frederic
    Hilpert, Felix
    Reuss, Alexander
    Savarese, Antonella
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Scotto, Nana
    Mitchell, Lada
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3836 - +
12345